Trial Profile
A retrospective, multicenter, observational study evaluating the efficacy and safety of eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jan 2017
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Thrombotic microangiopathy
- Focus Adverse reactions; Therapeutic Use
- 11 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology